CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 2,927 enrolled
Drug / intervention
General principles of care and judgement of researcherdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04072705
NCT04072705N/ACompleted

A Multicenter Prospective observationaL Study to evAluate the effecT of Clopidogrel on the prEvention of Major vascuLar Events According to the gEnotype of Cytochrome P450 2C19 in Ischemic Stroke paTients; PLATELET Study

Gangnam Severance Hospital·observational·Posted Aug 28, 2019·Updated Sep 25, 2023

In Brief

An observational study evaluating General principles of care and judgement of researcher for Acute Ischemic Stroke. Completed, enrolled 2,927 participants across 37 sites.

Detailed Summary

The hypothesis of this study is that "the poor metabolizer or intermediate metabolizer of the cytochrome P450 2C19 genotype in patients with acute ischemic stroke is associated with increased risk of composite cardiovascular events (recurrent stroke, myocardial infarction, cardiovascular death) compared to those who of extensive metabolizer of the cytochrome P450 2C19 genotype".

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesSouth Korea
CollaboratorsSAMJIN PHARM

Timeline

N/ACompletedFinished
2020202120222023202420252026
First PostedAug 28, 2019
Enrollment StartSep 20, 2019
Primary CompletionJan 11, 2023
Study CompletionJul 7, 2023
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 6.8 years ago

Interventions

General principles of care and judgement of researcherdrug

Because our study will be performed by observational design, there will be no intervention for our study. Because it is a registry-based study, overall decision making for medications will be performed according to the general principles of care and judgement of researcher.